Drug intelligence / Profile preview

compound 6e

Development stage: Preclinical
Lead developer: Cocrystal Pharma
Modality: Small Molecules

Overview

Compound 6e is a preclinical broad-spectrum antiviral compound developed by Kansas State University researchers. It functions as a 3C-like protease (3CLpro) inhibitor and has demonstrated activity against coronaviruses such as SARS-CoV-2 (COVID-19) and MERS-CoV, as well as noroviruses. Cocrystal Pharma acquired an exclusive, royalty-bearing license for this compound and related series in February 2020, with an expansion in April 2020, driven by the urgent need for COVID-19 treatments. At the time of the acquisition, the compound was in the preclinical stage, supported by data from cell cultures and a mouse model for MERS.

Other names: compound 6ecompound6ecompound-6e

Targets

Mpro (3C-like proteinase of SARS-CoV-2)MERS-CoV 3CLpro (MERS-CoV main protease)

Beyond the preview

Go deeper on compound 6e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 6e.

Explore the full profile